WO2025002299 - COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF COMPLEMENT FACTOR B (CFB)
National phase entry:
Publication Number
WO/2025/002299
Publication Date
02.01.2025
International Application No.
PCT/CN2024/102170
International Filing Date
28.06.2024
Title **
[English]
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF COMPLEMENT FACTOR B (CFB)
[French]
COMPOSITIONS ET PROCÉDÉS POUR INHIBER L'EXPRESSION DU FACTEUR B DU COMPLÉMENT (CFB)
Applicants **
SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD.
J2026, Room 1_203, 337 Shahe Road, Jiangqiao Town
Jiading District, Shanghai 201803, CN
Inventors
SHU, Dongxu
Room 201, No. 24, Lane 535, Qingnian Road, Qiuai Town, Yinzhou District
Ningbo, Zhejiang 315100, CN
SHAO, Pengcheng Patrick
631 Addison Way, Warrington Township
Pennsylvania 18976, US
XIA, Shiwei
Minqiang VillageLishan Town, Fuyang District
Hangzhou, Zhejiang 311400, CN
Priority Data
PCT/CN2023/103142
28.06.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CNIPA
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 3683 | |
| EPO | Filing, Examination | 42104 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 17560 |
Total: 64511 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Compositions and methods useful to reduce expression of CFB gene and for treatment of CFB-associated diseases and conditions are provided. Provided are CFB dsRNA agents, CFB antisense polynucleotide agents, compositions comprising CFB dsRNA agents, and compositions comprising CFB antisense polynucleotide agents that can be used to reduce CFB expression in cells and subjects.[French]
L'invention concerne des compositions et des procédés utiles pour réduire l'expression du gène CFB et pour le traitement de maladies et d'états associés à CFB. L'invention concerne des agents ARNdb du CFB, des agents polynucléotidiques antisens du CFB, des compositions comprenant des agents ARNdb du CFB, et des compositions comprenant des agents polynucléotidiques antisens du CFB qui peuvent être utilisés pour réduire l'expression de CFB chez des cellules et des sujets.